Abstract: The invention provides a method, device, kit and computer-implemented method for diagnosing (and optionally also treating) cancer. The method for diagnosing cancer comprises the step of testing a blood sample from a subject suspected of having cancer for the presence of Ipo5 (Importin 5) and at least one other biomarker, the at least one other biomarker being selected from Ran (Ras-related nuclear protein) and KpnB1 (Karyopherin beta 1). The blood sample may also be tested for additional biomarkers such as CRM1 (Cross-Reactive-Material-197), Kpna2 (Karyopherin alpha 2), CAS (Cellular apoptosis-susceptibility protein) and Transportin 1.

Abstract: This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety radiolabeled with a radionuclide. Radiolabeled compounds of the invention may be used in targeted radionuclide therapy wherein a patient is treated with a compound of the invention comprising a diagnostic radionuclide to identify the presence of a cancer or disease, followed by treatment with a compound of the invention comprising a therapeutic radionuclide to treat said cancer or disease.

Abstract: Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.

Abstract: Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.

Abstract: Compounds, including quinoxaline derivatives of formula I, for use in the treatment of cancer are described. In general, the compounds inhibit the import of proteins and transcription factors such as Kpn?, AP-1, P65, NFAT into the nucleus of a cell by inhibiting the nuclear import protein, Kpn?1. Cancer cells have elevated levels of Kpn?1 and the inhibition of their nuclear import activity induces cell apoptosis. The administration of an effective amount of any one of the compounds results in cell apoptosis in cancer cells, while non-cancer cells are substantially unaffected by the inhibition of Kpn?1's nuclear import activity.

Abstract: Compounds, including quinoxaline derivatives of Formula (I), for use in the treatment of cancer are described. In general, the compounds inhibit the import of proteins and transcription factors such as Kpn?, AP-1, P65, NFAT into the nucleus of a cell by inhibiting the nuclear import protein, Kpn?1. Cancer cells have elevated levels of Kpn?1 and the inhibition of their nuclear import activity induces cell apoptosis. The administration of an effective amount of any one of the compounds results in cell apoptosis in cancer cells, whilst non-cancer cells are substantially unaffected by the inhibition of Kpn?1's nuclear import activity.